Hoffmann-la Roche

This study is testing an experimental drug called giredestrant for people with a specific type of advanced breast cancer that has grown despite one or two prior treatments. It compares giredestrant to the hormone therapy a doctor would normally choose. The main goal is to see if …

This study is testing a drug called alectinib, combined with standard chemotherapy, for people with early-stage lung cancer that can be surgically removed. It aims to see if giving this combination before or after surgery is safe and helps prevent the cancer from coming back. The…

This early-stage study is testing the safety of a new treatment for advanced dry age-related macular degeneration (AMD), a leading cause of vision loss. Doctors are injecting lab-grown retinal cells derived from human embryonic stem cells into the eyes of 24 patients with severe …

This study is testing whether a drug called atezolizumab can help prevent cancer from returning in people with high-risk bladder cancer who have had their bladder surgically removed. The trial will involve about 761 participants who have a specific blood marker suggesting a high …

This study is testing whether satralizumab, an injectable medication, can help control moderate-to-severe thyroid eye disease. About 131 participants will receive either the drug or a placebo to see if it reduces eye bulging, double vision, pain, and improves quality of life. The…

This study is testing whether a higher dose of the drug ocrelizumab can better slow the worsening of disability in adults with primary progressive multiple sclerosis (PPMS). It compares the new higher dose against the currently approved dose over at least two years. The main goal…

This study is testing a daily oral medicine called risdiplam in infants who have been diagnosed with spinal muscular atrophy (SMA) but do not yet show symptoms. The goal is to see if starting treatment very early can help control the disease and allow babies to reach important mo…

This large, late-stage study is testing whether a drug called atezolizumab can help prevent non-small cell lung cancer from returning after patients have had surgery and chemotherapy. The trial will compare giving atezolizumab for about a year to providing only best supportive ca…

This study is comparing two treatments for a serious kidney disease called primary membranous nephropathy, which causes the body to lose too much protein in urine. Researchers are testing whether a drug called obinutuzumab works better and is safer than the standard treatment, ta…

This study is testing an investigational drug called crovalimab in children with atypical hemolytic uremic syndrome (aHUS), a rare and serious disease that damages the kidneys. The goal is to see if the drug can safely control the disease by blocking part of the immune system tha…

This study is testing several targeted drugs and immunotherapies for adults with advanced non-small cell lung cancer (NSCLC). It uses a simple blood test to find specific cancer markers and match patients to the most promising treatment for their cancer type. The main goals are t…

This study is testing a daily oral medication, RO7269162, to see if it is safe and if it can reduce the buildup of certain proteins in the brains of people who are at risk for or in the very early stage of Alzheimer's disease. It will involve about 256 participants who either hav…

This early-stage clinical trial is testing a new experimental drug called RO7247669 in people with advanced solid tumors that have spread. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it might help shrink tumors. The …

This study allows patients with solid tumors who were already receiving pertuzumab in a previous Roche trial to continue treatment if they're still benefiting. It tracks how well the treatment controls cancer over the long term and monitors for any side effects. The goal is to pr…

This study is testing a new drug called divarasib against two existing drugs (sotorasib or adagrasib) for people with a specific type of advanced lung cancer (KRAS G12C-positive NSCLC) that has worsened after prior treatment. The main goal is to see if divarasib can better contro…

This study is checking if a preventive treatment called emicizumab helps protect joints and allows for more physical activity in teens and adults with moderate to severe hemophilia A. It will follow 136 participants for up to 3 years, using ultrasounds, activity trackers, and que…

This study is for people with a specific type of advanced breast cancer (HER2-positive and estrogen receptor-positive) that has not been treated before. It tests if adding a new drug called giredestrant to a standard two-drug therapy (Phesgo) works better than using the standard …

This large, late-stage study is testing whether a new oral medication called giredestrant works better than the doctor's choice of standard hormone therapy at preventing cancer from returning after surgery. It involves over 4,000 people with early-stage, hormone-sensitive breast …

This study compares two drug combinations for patients whose aggressive lymphoma has returned or stopped responding to previous treatments. Researchers are testing whether adding a new drug called glofitamab to standard chemotherapy works better and is safer than the current stan…

This study is testing whether adding a new immunotherapy drug (atezolizumab) to a standard chemotherapy and targeted therapy combination works better before surgery for people with a specific type of stomach or gastroesophageal cancer (HER2-positive). The goal is to shrink the tu…

This study is testing whether a new drug called tobemstomig, when given with standard chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer who haven't had treatment before. It will inv…

This study is testing whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to a standard liver cancer treatment called TACE works better than TACE alone. It involves 342 people with untreated liver cancer who are at high risk of their cancer worsening after TACE.…

This study is testing a new drug called RO7126209 in people with early-stage Alzheimer's disease. The main goals are to check if the drug is safe and to see if it can reduce the amount of amyloid plaque, a key protein buildup, in the brain. The drug is given by IV infusion, and p…

This large, late-stage study is testing whether a new daily oral medication, fenebrutinib, can slow the worsening of disability in adults with primary progressive multiple sclerosis (PPMS). It directly compares fenebrutinib against an existing intravenous (IV) treatment, ocrelizu…

This study is testing an investigational drug called RO7204239 to see if it can increase muscle volume and slow disease progression in adults with FSHD, a genetic muscle-wasting disorder. The trial will measure changes in muscle size using MRI scans and check the drug's safety. P…

This large, late-stage study is testing whether a new oral drug called fenebrutinib works better and is as safe as the established drug teriflunomide for adults with relapsing multiple sclerosis (RMS). About 750 participants are randomly assigned to take one of the two pills to s…

This study is testing an investigational drug called crovalimab in adults and adolescents with atypical hemolytic uremic syndrome (aHUS), a rare and serious blood disorder that can damage the kidneys. The main goal is to see if the drug can effectively control the disease and is …

This study follows 1000 Chinese adults with diffuse large B-cell lymphoma (DLBCL) to see how well the drug polatuzumab works in real-world clinical practice. It aims to measure how long patients live without their cancer getting worse and to monitor side effects. The study includ…

This early-stage study is testing a new drug called crovalimab for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disease. The main goals are to check if the drug is safe, how the body processes it, and if it can help control the disease. The stud…

This study is testing whether adding a new investigational drug called RO7204239 to the approved SMA drug risdiplam is safe and more effective. RO7204239 is designed to block a protein that limits muscle growth, potentially helping muscles get bigger and stronger. The trial will …

This study follows 1,300 multiple sclerosis patients who previously received ocrelizumab in earlier trials. Researchers will monitor patients for several years to understand the long-term safety and effectiveness of continued treatment. The study tracks disability progression, wa…

This large, late-stage study is testing whether adding a new drug called tiragolumab to an existing immunotherapy (atezolizumab) can better control advanced esophageal cancer that cannot be surgically removed. The trial involves 760 people whose cancer did not worsen after initia…

This study is testing whether adding an investigational drug called obinutuzumab to standard lupus therapy is better at controlling the disease than standard therapy alone. It involves about 300 adults with active, antibody-positive lupus. The main goal is to see if the drug help…

This study is testing if adding a new drug called tiragolumab to a standard two-drug treatment helps people with advanced liver cancer that cannot be surgically removed. It will compare the three-drug combination against the standard two-drug combination to see which is better at…

This study is testing whether adding an experimental drug called glofitamab to standard chemotherapy (R-CHOP) works better for people with high-risk, untreated diffuse large B-cell lymphoma. Researchers will enroll about 46 patients who have specific high-risk markers in their bl…

This study is testing whether a new immunotherapy drug called tobemstomig, when combined with standard chemotherapy, works better than the current standard treatment for advanced triple-negative breast cancer. It involves 83 people with a specific type of this aggressive cancer t…

This study is testing several personalized treatments for women whose rare types of ovarian cancer have persisted or returned after prior therapy. Doctors will use specific markers found in a patient's tumor to match them to one of the investigational treatments. The main goal is…

This study is testing a new drug called zifibancimig for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is being given as eye injections and through a small, refillable implant placed in the eye. The main goals are to see if the d…

This study is testing whether adding a new immunotherapy drug (tiragolumab) to an existing one (atezolizumab) can help eliminate rectal cancer more effectively after patients receive standard chemoradiation. The goal is to see if the drugs can destroy all cancer cells in the remo…

This study is testing whether adding a new drug called tiragolumab to a standard treatment regimen can better control advanced small cell lung cancer. It involved 123 patients in China who had not yet received any treatment for their extensive-stage disease. The goal is to see if…

This study is testing whether a refillable implant placed in the eye can safely deliver vision medication for wet age-related macular degeneration (AMD) less frequently. Researchers are comparing refilling the implant every 36 weeks versus every 24 weeks to see if the longer inte…

This study is testing a drug called entrectinib for people with advanced solid tumors that have specific genetic changes (NTRK, ROS1, or ALK gene rearrangements). It's a 'basket trial,' meaning it groups patients by their tumor's genetic type rather than where the cancer started …

This study allows cancer patients who were benefiting from atezolizumab treatment in previous Roche-sponsored trials to continue receiving their therapy. It's designed for patients who don't have access to this treatment through regular commercial channels in their country. The s…

This study tests an experimental drug called cevostamab for people with advanced multiple myeloma that has returned or stopped responding to other treatments. It involves 90 participants who have already tried specific targeted therapies. The main goals are to see if the drug hel…

This study allows patients with ALK- or RET-positive cancers who benefited from alectinib or crizotinib in previous Roche trials to continue receiving the drug after those trials end. It aims to provide ongoing treatment access while monitoring safety in about 200 participants. T…

This study is testing a drug called entrectinib in children and adolescents with advanced solid tumors or brain cancers that have come back or not responded to other treatments. The main goals are to find the safest and most effective dose and to see if the drug helps shrink tumo…

This study is testing if a drug called obinutuzumab works better than the standard drug MMF to keep a childhood kidney disease from coming back. It involves 85 children and young adults (ages 2-25) who have a form of the disease that frequently relapses. The main goal is to see w…

This study is testing new combinations of immunotherapy and targeted drugs for adults with B-cell non-Hodgkin's lymphoma that has returned or stopped responding to previous treatments. The main goals are to find safe and effective doses and to see if these combinations can shrink…

This study is testing an experimental drug called tominersen to see if it is safe and can slow the progression of Huntington's disease in people who are in the very early stages. About 300 participants will receive either the drug or a placebo (inactive substance) for 16 months, …

This study is testing a small, refillable implant placed in the eye to slowly release a medicine (ranibizumab) over time. It aims to see if this device is better than standard injections at improving diabetic retinopathy and preventing serious vision complications. The trial invo…

This large, late-stage study is testing whether a higher dose of the approved MS drug ocrelizumab works better than the standard dose at slowing disability progression. It will involve 864 adults with relapsing MS, who will receive intravenous infusions every 24 weeks and be moni…

This large Phase 3 trial is testing whether a new drug called giredestrant, when combined with palbociclib, works better than the current standard treatment (letrozole + palbociclib) for people with a specific type of advanced breast cancer. The study involves 992 patients whose …

This study is testing a preventive drug called emicizumab in babies under 1 year old who have severe hemophilia A, a serious genetic bleeding disorder. The main goal is to see if regular injections can safely reduce the number of bleeding episodes these infants experience. After …

This study is testing whether a new drug called crovalimab works as well as the current standard treatment (eculizumab) for controlling paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disease. It involves 210 adults with PNH who have never taken this type of m…

This study is testing a new daily medication called RO7795081 to see if it helps adults with obesity or overweight lose weight and manage related health conditions like high blood pressure. About 340 participants will take either the medication or a placebo (inactive pill) for 38…

This study is comparing two oral medications, entrectinib and crizotinib, for people with advanced non-small cell lung cancer that has a specific genetic change called ROS1. The main goal is to see which drug is better at delaying cancer growth, especially for patients whose canc…

This large, late-stage study is testing whether the drug ocrelizumab (Ocrevus®) can slow down the worsening of disability in adults with primary progressive multiple sclerosis (PPMS). Over 1,000 participants were randomly assigned to receive either the drug or a placebo (inactive…

This study is testing whether adding an immunotherapy drug (atezolizumab) to standard breast cancer treatment helps prevent the cancer from coming back in high-risk patients. It involves about 1,200 people with HER2-positive breast cancer who still had cancer cells after their in…

This study is testing an oral medication called giredestrant in 30 patients with early-stage, low-grade endometrial cancer. The main goal is to see if the drug can shrink or eliminate the cancer cells in the uterus after six months of treatment. Researchers will monitor how well …

This large, late-stage study is testing if adding a new immunotherapy drug called glofitamab to a standard chemotherapy regimen works better for people newly diagnosed with a fast-growing type of lymphoma. It will involve over 1,100 participants to see if the new combination help…

This study is for adults with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. It compares a new combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) against a standard chemotherapy regimen. The goal is to see if t…

This large, late-stage study is testing whether an experimental oral drug called fenebrutinib works better and is as safe as an approved medication, teriflunomide, for adults with relapsing multiple sclerosis (RMS). About 746 participants will be randomly assigned to take one of …

This study is testing whether an intravenous drug called prasinezumab can slow the worsening of movement problems in people with early Parkinson's disease. About 586 participants who are already on stable Parkinson's medication will receive either the drug or a placebo (inactive …

This study is testing personalized drug combinations for people with a specific type of advanced lung cancer (Stage III NSCLC) that cannot be removed by surgery. It aims to see if adding new targeted drugs to standard treatment can better control the cancer and prevent it from sp…

This early-stage study is testing the safety and dosing of an experimental drug called forimtamig in people with advanced multiple myeloma that has returned or stopped responding to standard treatments. The trial will enroll about 225 participants who have exhausted other options…

This study is testing whether a new eye injection called faricimab works as well as the standard treatment (ranibizumab) for controlling abnormal blood vessel growth that damages vision in people with severe nearsightedness. About 280 participants with this specific eye condition…

This 4-year study is testing the effectiveness and safety of the drug ocrelizumab in people with progressive multiple sclerosis (PMS). It involves 927 participants and aims to see if the treatment can stop or slow the worsening of physical and cognitive disabilities. The main goa…

This study is testing whether a targeted pill called alectinib works better than standard chemotherapy to prevent lung cancer from coming back after surgery. It involves patients whose lung cancer has been completely removed and who have a specific genetic marker (ALK-positive). …

This study is for people with advanced liver cancer that has continued to grow despite receiving a specific prior treatment (atezolizumab plus bevacizumab). It aims to see if adding the drug atezolizumab to one of two other cancer drugs (lenvatinib or sorafenib) helps patients li…

This study is testing whether the drug crovalimab can safely control paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease where the immune system destroys red blood cells. The trial includes about 50 people aged 12 and older with PNH who have never taken similar comple…

This study is testing whether an experimental drug called fenebrutinib can reduce brain inflammation in people with relapsing multiple sclerosis. About 109 participants will receive either fenebrutinib or a placebo for 12 weeks, with researchers using brain scans to measure chang…

This study compares two different drug combinations for people with follicular lymphoma that has returned or stopped responding to previous treatment. Researchers want to see if a newer drug called mosunetuzumab works better than the standard drug rituximab when both are given wi…

This large, late-stage study is testing whether an investigational drug called Afimkibart can help people with moderate-to-severe ulcerative colitis achieve and maintain remission. About 400 participants will receive either the drug or a placebo for a year to see if it reduces bo…

This study is testing whether adding a new investigational drug called RO7204239 to an existing weight-loss medication (tirzepatide) helps people lose more weight. It will involve about 285 adults who have obesity or are overweight with at least one related health issue, like hig…

This study is testing if a medication called faricimab, given as an injection into the eye, can effectively control 'wet' age-related macular degeneration (AMD) while allowing for less frequent treatments. It involves about 274 people who have not yet received treatment for this …

This study is testing the safety and biological activity of an experimental gene therapy in very young children with Duchenne muscular dystrophy (DMD). It involves 13 children under 4 years old who will receive a single dose of the therapy and be followed for about 5 years. The m…

This study allows cancer patients who were benefiting from atezolizumab treatment in previous Roche-sponsored trials to continue receiving their medication if it's not available through regular channels. The 49 participants can keep getting their treatment while researchers monit…

This study allows cancer patients who were benefiting from atezolizumab treatment in previous Roche-sponsored trials to continue receiving their medication after those trials close. The research monitors 382 participants to track long-term safety and survival outcomes while provi…

This is an early-stage study to check the safety and find the right dose of a new drug called RO7567132. It is being tested alone and in combination with an existing immunotherapy drug (atezolizumab) in adults with advanced solid cancers that have not responded to standard treatm…

This Phase 3 study is testing whether an injectable medication called satralizumab can help people with moderate-to-severe thyroid eye disease. The trial will measure if the treatment reduces eye bulging, eases pain and double vision, and improves quality of life. It involves 127…

This early-stage study is testing a new oral medication called ZN-A-1041 for people with advanced HER2-positive cancers that have spread or returned after treatment. Researchers will give the drug alone or combined with other standard cancer therapies to about 210 participants to…

This study tested whether adding the drug obinutuzumab to standard lupus nephritis treatment helps control the disease and protect kidney function better than standard treatment alone. It involved 271 adults with active, serious kidney inflammation caused by lupus. Researchers co…

This large, late-stage trial is testing whether adding a newer targeted drug (polatuzumab vedotin) to a standard chemotherapy regimen works better for people newly diagnosed with an aggressive type of blood cancer called diffuse large B-cell lymphoma. It will compare the new comb…

This study is testing a new injectable medication called Afimkibart for adults with moderate to severe Crohn's disease who haven't gotten enough relief from standard treatments. Researchers want to see if the treatment is safe and if it can reduce gut inflammation and symptoms li…

This large, late-stage trial is testing whether a combination of two immunotherapy drugs (atezolizumab and bevacizumab) can help prevent liver cancer from returning in patients who are at high risk after their initial tumor was surgically removed or destroyed. It compares giving …

This study is for people with a specific type of advanced breast cancer that has a genetic change called PIK3CA and has continued to grow despite standard hormone-based therapy. It aims to see if a new drug combination (inavolisib + fulvestrant) works better and is safer than an …

This study is testing whether an intravenous drug called prasinezumab can slow the progression of Parkinson's disease in people who are in the early stages. Over 300 participants will receive either the drug or a placebo for one year, with the option to continue treatment for up …

This study is testing whether an immunotherapy drug called atezolizumab can help people with advanced non-small cell lung cancer who haven't had chemotherapy yet. The trial includes 60 patients whose cancer has spread (stage IV) and shows high levels of a protein called PD-L1. Re…

This early-stage study is testing the safety and initial effects of an investigational drug called RO7790121 in 50 people with advanced MASH-related liver scarring (fibrosis). The main goal is to see how well the drug is tolerated and how it behaves in the body. Researchers will …

This study is testing two new immunotherapy drugs, alone and together, against an existing drug for advanced bladder cancer. It is for patients whose cancer has spread and who are not healthy enough for standard platinum-based chemotherapy. The main goal is to see if the new trea…

This study is testing whether a new drug called crovalimab, when added to a patient's usual sickle cell treatments, can help prevent the severe pain episodes known as vaso-occlusive crises. It will involve about 90 participants with sickle cell disease who have experienced severa…

This study is testing a new drug called englumafusp alfa, given with other approved lymphoma drugs, for people whose Non-Hodgkin's lymphoma has come back or hasn't responded to previous treatments. The main goals are to find a safe dose and see if the combination can shrink tumor…

This study is testing the safety and determining the right dose of the drug ocrelizumab for children and teenagers (ages 10-18) with relapsing-remitting multiple sclerosis (MS). It involves a small group of 23 participants and will last for two years. The main goal is to gather i…

This study aimed to test whether adding crovalimab to standard blood thinners could better prevent dangerous blood clots in people with antiphospholipid syndrome. The trial was designed for adults with a history of blood clots who were already taking blood-thinning medication. Ho…

This study compares two targeted drugs, alectinib and crizotinib, for Asian patients with a specific type of advanced lung cancer (ALK-positive) who haven't had prior treatment. Researchers want to see which drug better controls the cancer for longer and is safer. The trial invol…

This study is testing whether adding a new drug called inavolisib to two standard breast cancer medications works better than the standard medications alone. It is for people with a specific type of advanced breast cancer (HR+/HER2- with a PIK3CA mutation) that has worsened after…

This study was designed to test whether adding a new drug called inavolisib to standard chemotherapy could better control advanced colorectal cancer that has spread and has a specific genetic change (PIK3CA mutation). It was intended for people who had not yet received treatment …

This study is testing whether a new drug called crovalimab works as well as or better than the standard treatment (eculizumab) for controlling paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. It will involve about 190 people who are already being treated for PNH.…

This study is testing two new combinations of immunotherapy drugs and a targeted therapy (axitinib) for people with advanced kidney cancer that cannot be removed by surgery. It will compare these new combinations to a current standard treatment (pembrolizumab + axitinib) to see i…

This study compares two medications for children and teens with relapsing multiple sclerosis (MS). Researchers want to see if ocrelizumab (given by IV every 6 months) works better and is safer than fingolimod (taken as a daily pill) in controlling MS attacks. About 188 young peop…

This large Phase 3 trial is testing whether adding the drug lurbinectedin to standard maintenance therapy (atezolizumab) helps people with extensive-stage small-cell lung cancer live longer without their cancer getting worse. The study involves 660 participants whose cancer respo…

This study aims to understand how well the drug alectinib works for people with a specific type of advanced lung cancer (ALK-positive NSCLC) in real-world settings, outside of a controlled clinical trial. It will follow 800 patients already receiving this treatment as part of the…

This study aims to collect long-term, real-world information on how patients with serious eye conditions like macular degeneration and diabetic eye swelling respond to specific Roche eye injection treatments. It will observe 6,000 patients already receiving these approved treatme…

This study is observing nearly 3,000 newly diagnosed breast cancer patients across Latin America to understand how the disease is treated and what outcomes patients experience. Researchers are collecting information about patient characteristics, treatment approaches, and surviva…

This study observes 1,200 patients in China with advanced, inoperable non-small cell lung cancer. It aims to understand how patients are actually treated in real-world clinics, what their survival outcomes are, and the financial costs they face. The study collects data from medic…

This study is observing how well the immunotherapy drug atezolizumab works and its safety for patients with advanced lung, bladder, or liver cancer in real-world medical settings. It involves over 2,700 patients who are already receiving this drug as part of their standard care. …